|
Name |
Atromentin
|
Molecular Formula | C18H12O6 | |
IUPAC Name* |
2,5-dihydroxy-3,6-bis(4-hydroxyphenyl)cyclohexa-2,5-diene-1,4-dione
|
|
SMILES |
C1=CC(=CC=C1C2=C(C(=O)C(=C(C2=O)O)C3=CC=C(C=C3)O)O)O
|
|
InChI |
InChI=1S/C18H12O6/c19-11-5-1-9(2-6-11)13-15(21)17(23)14(18(24)16(13)22)10-3-7-12(20)8-4-10/h1-8,19-21,24H
|
|
InChIKey |
FKQQKMGWCJGUCS-UHFFFAOYSA-N
|
|
Synonyms |
Atromentin; 519-67-5; 2,5-dihydroxy-3,6-bis(4-hydroxyphenyl)cyclohexa-2,5-diene-1,4-dione; 2,5-dihydroxy-3,6-bis(4-hydroxyphenyl)-1,4-benzoquinone; CHEMBL4593579; NSC-187730; p-Benzoquinone, 2,5-dihydroxy-3,6-bis(p-hydroxyphenyl)-; 2,5-Cyclohexadiene-1,4-dione, 2,5-dihydroxy-3,6-bis(4-hydroxyphenyl)-; 59557692U6; NSC 187730; SCHEMBL9176577; DTXSID60199863; CHEBI:149660; BDBM50536674; NSC187730; UNII-59557692U6; Q4817643; p-Benzoquinone,5-dihydroxy-3,6-bis(p-hydroxyphenyl)-; 2,4-dione, 2,5-dihydroxy-3,6-bis(4-hydroxyphenyl)-; 2,5-dihydroxy-3,6-bis(p-hydroxyphenyl)-p-benzoquinone; 2,5-Dihydroxy-3,6-bis(4-hydroxyphenyl)benzo-1,4-quinone #; 3',4,4'',6'-tetrahydroxy[1,1':4',1''-terphenyl]-2',5'-dione; 2,5-DIHYDROXY-3,6-BIS(4-HYDROXYPHENYL)-2,5-CYCLOHEXADIENE-1,4-DIONE; 1(4),2(3),2(6),3(4)-tetrahydroxy[1(1),2(1):2(4),3(1)-terphenyl]-2(2),2(5)-dione
|
|
CAS | 519-67-5 | |
PubChem CID | 99148 | |
ChEMBL ID | CHEMBL4593579 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 324.3 | ALogp: | 2.3 |
HBD: | 4 | HBA: | 6 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 115.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 24 | QED Weighted: | 0.63 |
Caco-2 Permeability: | -4.786 | MDCK Permeability: | 0.00000629 |
Pgp-inhibitor: | 0.008 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.011 | 20% Bioavailability (F20%): | 0.002 |
30% Bioavailability (F30%): | 0.028 |
Blood-Brain-Barrier Penetration (BBB): | 0.034 | Plasma Protein Binding (PPB): | 97.36% |
Volume Distribution (VD): | 0.317 | Fu: | 1.11% |
CYP1A2-inhibitor: | 0.674 | CYP1A2-substrate: | 0.091 |
CYP2C19-inhibitor: | 0.183 | CYP2C19-substrate: | 0.051 |
CYP2C9-inhibitor: | 0.62 | CYP2C9-substrate: | 0.918 |
CYP2D6-inhibitor: | 0.566 | CYP2D6-substrate: | 0.159 |
CYP3A4-inhibitor: | 0.384 | CYP3A4-substrate: | 0.088 |
Clearance (CL): | 0.791 | Half-life (T1/2): | 0.417 |
hERG Blockers: | 0.012 | Human Hepatotoxicity (H-HT): | 0.919 |
Drug-inuced Liver Injury (DILI): | 0.992 | AMES Toxicity: | 0.236 |
Rat Oral Acute Toxicity: | 0.393 | Maximum Recommended Daily Dose: | 0.029 |
Skin Sensitization: | 0.462 | Carcinogencity: | 0.041 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.013 |
Respiratory Toxicity: | 0.395 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002800 | 0.561 | D00LFB | 0.359 | ||||
ENC002755 | 0.547 | D09ZQN | 0.356 | ||||
ENC005038 | 0.547 | D0Y2NE | 0.356 | ||||
ENC000826 | 0.495 | D03UOT | 0.333 | ||||
ENC003373 | 0.477 | D0AL8M | 0.327 | ||||
ENC002571 | 0.468 | D04AIT | 0.319 | ||||
ENC005869 | 0.448 | D06TJJ | 0.314 | ||||
ENC002756 | 0.436 | D0K8KX | 0.313 | ||||
ENC005410 | 0.430 | D01XBA | 0.310 | ||||
ENC001576 | 0.429 | D05VLS | 0.293 |